Mark E Hurtt
Overview
Explore the profile of Mark E Hurtt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
310
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lewin G, Hurtt M
Birth Defects Res
. 2017 Sep;
109(19):1519-1539.
PMID: 28876535
The purpose of this review is to give an outline of respiratory tract morphological and functional development with an emphasis on perinatal and postnatal maturational processes. In view of the...
2.
Comparative assessment of the timing of sexual maturation in male Wistar Han and Sprague-Dawley rats
Campion S, Carvallo F, Chapin R, Nowland W, Beauchamp D, Jamon R, et al.
Reprod Toxicol
. 2013 Feb;
38:16-24.
PMID: 23434729
Given the increasing use of Wistar Han (WH) rats in regulatory toxicology studies, these studies were performed to characterize the onset of sexual maturation in maturing WH rats as compared...
3.
Cappon G, Bowman C, Hurtt M, Grantham 2nd L
Birth Defects Res B Dev Reprod Toxicol
. 2012 Aug;
95(5):354-62.
PMID: 22930561
An important aspect of the enhanced pre- and postnatal developmental (ePPND) toxicity study in nonhuman primates (NHP) is that it combines in utero and postnatal assessments in a single study....
4.
Campion S, Bowman C, Cappon G, Harrison A, Finch G, Hurtt M
Birth Defects Res B Dev Reprod Toxicol
. 2012 Apr;
95(3):250-61.
PMID: 22495820
Background: Lersivirine is a second-generation nonnucleoside reverse transcriptase inhibitor undergoing clinical development for the treatment of human immunodeficiency virus-1. An embryo-fetal development study was performed to evaluate the potential for...
5.
Campion S, Davenport S, Nowland W, Cappon G, Bowman C, Hurtt M
Birth Defects Res B Dev Reprod Toxicol
. 2012 Apr;
95(3):238-49.
PMID: 22495808
The critical periods of axial skeletal development in rats and mice have been well characterized, however the timing of skeletal development in rabbits is not as well known. It is...
6.
Cappon G, Bowman C, Campion S, Chmielewski G, Hurtt M, Finch G, et al.
Birth Defects Res B Dev Reprod Toxicol
. 2012 Mar;
95(3):225-30.
PMID: 22447726
Lersivirine is a second-generation nonnucleoside reverse transcriptase inhibitor undergoing clinical development for the treatment of HIV-1. An embryo-fetal developmental toxicity study was performed to evaluate the maternal and developmental toxicity...
7.
DeSesso J, Williams A, Ahuja A, Bowman C, Hurtt M
Crit Rev Toxicol
. 2012 Feb;
42(3):185-210.
PMID: 22348352
Anatomical and developmental differences of the parental-offspring interface among experimental animals and humans throughout gestation are reviewed focusing on biodistribution of immunoglobulins (IgG). The formation of the extraembryonic membranes, uteroplacental...
8.
Mansell P, Robinson K, Minck D, Hurtt M, Cappon G
Birth Defects Res B Dev Reprod Toxicol
. 2011 Aug;
92(4):345-52.
PMID: 21818842
Background: Pantoprazole is an irreversible inhibitor of H(+) /K(+) adenosine triphosphatase proton pump. This study encompassed the period of postnatal stomach development to determine whether immature animals are uniquely sensitive...
9.
Hurtt M
Birth Defects Res B Dev Reprod Toxicol
. 2011 Jul;
92(4):251.
PMID: 21770022
No abstract available.
10.
Cappon G, Chapin R, Hurtt M, Wajnrajch M, Burns-Naas L
Birth Defects Res B Dev Reprod Toxicol
. 2011 Jun;
92(4):304-13.
PMID: 21678547
Background: Exemestane is an irreversible steroidal inhibitor of cytochrome-P450 aromatase required for estrogen synthesis. The safety of the drug in the pediatric population, particularly in males, has not previously been...